<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089344</url>
  </required_header>
  <id_info>
    <org_study_id>GH in poor responders</org_study_id>
    <nct_id>NCT05089344</nct_id>
  </id_info>
  <brief_title>Growth Hormone Pretreatment in Poseidon Type IV Undergoing ICSI Using Minimal Induction Protocol: A Randomized Controlled Trial</brief_title>
  <acronym>Growth hormone</acronym>
  <official_title>Growth Hormone Pretreatment in Poseidon Type IV Undergoing ICSI Using Minimal Induction Protocol: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams Maternity Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is done aiming to Assess Efficiency of Growth hormone as an adjuvant in&#xD;
      pretreatment of Poseidon type IV group &quot; poor responders &quot;undergoing ICSI using minimal&#xD;
      induction protocol&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are recruited from the attendee of the Infertility clinic and IVF unit in maternity&#xD;
      hospital Ain shams university who are eligible for the trial.&#xD;
&#xD;
      Procedure will be done by Prof . Dr Mostafa Fouad . and Lecturer Dr Ebtihal ElTaieb&#xD;
&#xD;
      * Proper history taking, examination and investigations to:&#xD;
&#xD;
        -  exclude other causes of infertility.&#xD;
&#xD;
        -  Menstrual history: for assessment of oligo- or anovualtion.&#xD;
&#xD;
        -  Medical history: .&#xD;
&#xD;
        -  Past history: previous infertility treatment attempts or ovarian hyperstimulation&#xD;
           syndrome.&#xD;
&#xD;
        -  Obstetric history: for recurrent pregnancy loss.&#xD;
&#xD;
        -  Clinical examination, including:&#xD;
&#xD;
        -  Arterial blood pressure measurement&#xD;
&#xD;
        -  Assessment of hirsutism via modified Ferriman-Gallwey score&#xD;
&#xD;
        -  Assessment of alopecia and acne.&#xD;
&#xD;
        -  Hormonal profile assessment: basal serum FSH, LH, E2, progesterone, AMH, total serum&#xD;
           testosterone, SHBG (for calculation of FAI), DHEA, DHEAS, TSH, prolactin and 24-hour&#xD;
           urinary free cortisol (to rule out Cushing's syndrome).&#xD;
&#xD;
        -  Semen analysis: to rule out male cause of infertility as teratospermia or azospermia.&#xD;
&#xD;
        -  Transvaginal ultrasonography: by the same experienced gynecological sonographer using a&#xD;
           Voluson E6 Expert ultrasound machine (General Electric®, Fairfield, CT, USA) for U/S&#xD;
           criteria of PCOS, AFC and exclusion any uterine or pelvic pathologies.&#xD;
&#xD;
        -  Hysterosalpingography (HSG): to exclude any uterine, tubal or peritoneal abnormalities.&#xD;
&#xD;
      Patients fitting inclusion and exclusion criteria will be randomized to either study groups.&#xD;
      A computer generated list via MedCalc ® Software, version 13.2.2 will be used, assigning each&#xD;
      participant number to either study groups. Assignment will be done by sequentially numbered,&#xD;
      otherwise identical, sealed envelopes (SNOSE), each containing a 2-inch by 2-inch paper with&#xD;
      a written code designating the assigned group. These papers will be placed in a folded sheet&#xD;
      of aluminum foil fitted inside the envelope. Effort will be taken to assure absence of any&#xD;
      detectable differences in size or weight between intervention and control envelopes.&#xD;
      Envelopes will be chosen to be opaque and lined inside with carbon paper. Envelopes will be&#xD;
      opened sequentially only after writing the subject's tracking information on the envelope so&#xD;
      that the carbon paper served as an audit trail.&#xD;
&#xD;
      After enrollment each patient randomly pick an envelope carrying a number, so that patients&#xD;
      will not be aware of the assignment (single blind technique), then the controlled ovarian&#xD;
      stimulation protocol will be applied according to letter enclosed (A or B) guided by the&#xD;
      computer based randomization table.&#xD;
&#xD;
      The patients were randomly assigned to one of the two parallel groups:&#xD;
&#xD;
        -  Group A: mild stimulation protocol + growth hormone adjuvant&#xD;
&#xD;
        -  Group B: Mild stimulation protocol&#xD;
&#xD;
      Study Interventions: Patients in both groups received mild stimulation protocol:&#xD;
&#xD;
      Controlled ovarian hyperstimulation protocol will be held according to a flexible GnRH&#xD;
      antagonist protocol + Clomophine citrate.&#xD;
&#xD;
      Ovarian stimulation will start with a fixed daily dose of 100 mg of Clomiphene citrate daily&#xD;
      and recombinant FSH (Gonal-F®) will be started on day 2 of the menstrual cycle at a dose of&#xD;
      150 IU to be adjusted thereafter in a step up fashion every 2 to 4 days according to ovarian&#xD;
      response (Kolibianakis et al., 2011).&#xD;
&#xD;
      . For those in the GH group, 8 IU recombinant human GH will be administered starting from Day&#xD;
      14 of the previous cycle Till administration of HCG for ovulation triggering, while those in&#xD;
      the control group will receive the same stimulation protocol without the adjuvant GH&#xD;
      treatment.&#xD;
&#xD;
        -  Follow up TVU/S will be done every other day starting day 6 of stimulation.&#xD;
&#xD;
        -  Cetrotide® 0.25 mg will be started when at least one of the following criteria is met:&#xD;
           LH &gt;10 IU/L, presence of a follicle with mean diameter &gt;12 mm, and serum E2 level &gt;150&#xD;
           pg/mL and continued until HCG administration.&#xD;
&#xD;
        -  When the leading follicle reaches 16 mm, TV U/S will be performed daily till the largest&#xD;
           follicle reach a diameter of &gt;18mm. The maximum duration of rFSH stimulation will not be&#xD;
           allowed to exceed day 16.&#xD;
&#xD;
        -  OOCYTE RETRIEVAL, FERTILIZATION AND EMBRYO TRANSFER&#xD;
&#xD;
        -  Ovarian pick up will be done 36 hours after HCG injection, the transducer will be&#xD;
           connected to the ultrasound system. The direction of the guide beam will be checked. The&#xD;
           puncturing needle will be connected to an aspiration apparatus attached by a fixation&#xD;
           ring to the front and rear ends of the vaginal transducer, thereby defining the&#xD;
           direction of puncture corresponding to the guide beam on the ultrasound image. Oocytes&#xD;
           will be aspirated using the standard aspiration technique using Wallace® 101 catheter&#xD;
           (Smiths medical®, Minnesota, USA) using aspiration pressure 90-100mmHg using flushing&#xD;
           technique.&#xD;
&#xD;
      To maximize the number of oocytes recovered, follicular aspiration followed by a single 2-mL&#xD;
      flush using embryo culture media. After initial aspiration, follicles were flushed and&#xD;
      aspirated three times each with 2 mL flushing medium .&#xD;
&#xD;
        -  Intracytoplasmic sperm injection will be performed on metaphase II oocytes using the&#xD;
           direct penetration technique. Fertilization results will be assessed 16 to 19 hours&#xD;
           after ICSI. Fertilization will be considered normal by the presence of two pronuclei.&#xD;
           Oocyte degeneration was identified by collapse of cytoplamic contents and separation&#xD;
           from the zona. Failed fertilization will be defined by the absence of the pronuclei.&#xD;
&#xD;
        -  Embryo transfer will be performed on day 3 of ICSI, using ultrasound guidance in the&#xD;
           midcorporeal part of the uterine cavity using soft Wallace® transfer catheter (Smiths&#xD;
           medical®, Minnesota, USA).&#xD;
&#xD;
        -  Luteal phase will be supported by natural progesterone in the form of vaginal&#xD;
           suppositories 400 mg twice daily starting from the day of oocyte retrieval till&#xD;
           pregnancy test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>20 week of gestation</time_frame>
    <description>pregnancy continuing after 20th week of gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Biochemical pregnancy rate</measure>
    <time_frame>2 weeks after embryo transfer</time_frame>
    <description>will be determined by positive pregnancy test performed 2 weeks after embryo transfer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Poor Response to Ovulation Induction Poseidon Type IV</condition>
  <arm_group>
    <arm_group_label>mild stimulation protocol + growth hormone adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Controlled ovarian hyperstimulation protocol will be held according to a flexible GnRH antagonist protocol + Clomophine citrate.&#xD;
Ovarian stimulation will start with a fixed daily dose of 100 mg of Clomiphene citrate daily and recombinant FSH (Gonal-F®) will be started on day 2 of the menstrual cycle at a dose of 150 IU to be adjusted thereafter in a step up fashion every 2 to 4 days according to ovarian response .&#xD;
. For those in the GH group, 8 IU recombinant human GH will be administered starting from Day 14 of the previous cycle Till administration of HCG for ovulation triggering</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild stimuation protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Controlled ovarian hyperstimulation protocol will be held according to a flexible GnRH antagonist protocol + Clomophine citrate.&#xD;
Ovarian stimulation will start with a fixed daily dose of 100 mg of Clomiphene citrate daily and recombinant FSH (Gonal-F®) will be started on day 2 of the menstrual cycle at a dose of 150 IU to be adjusted thereafter in a step up fashion every 2 to 4 days according to ovarian response .&#xD;
.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone</intervention_name>
    <description>growth hormone</description>
    <arm_group_label>mild stimulation protocol + growth hormone adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene citrate daily and recombinant FSH (Gonal-F®)</intervention_name>
    <description>Clomiphene citrate daily and recombinant FSH (Gonal-F®)</description>
    <arm_group_label>Mild stimuation protocol</arm_group_label>
    <arm_group_label>mild stimulation protocol + growth hormone adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  -Age group between 35 to 42 years old&#xD;
&#xD;
          -  AFC &lt;5&#xD;
&#xD;
          -  AMH &lt;1.2 ng/ml&#xD;
&#xD;
          -  first IVF trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Serious and unstable disease, such as cerebrovascular, liver, and kidney disease&#xD;
             &quot;will be unfit for pregnancy&quot;.&#xD;
&#xD;
          -  History of malignant or border line tumors &quot;will be unfit for pregnancy&quot;.&#xD;
&#xD;
          -  Endocrine or metabolic disorder &quot;affecting quality of oocyte so affecting results&quot;.&#xD;
&#xD;
          -  Either one of the couple with chromosomal abnormalities &quot;affecting quality of oocyte&#xD;
             so affecting results&quot;.&#xD;
&#xD;
          -  Male partner with severe oligoasthenozoospermia or with teratozoospermia&quot;affecting&#xD;
             quality of embryo to be transfered so affecting results&quot;.&#xD;
&#xD;
          -  Any contraindications to growth hormone, pregnancy (to be ruled out and documented&#xD;
             before GH treatment).&#xD;
&#xD;
          -  female patients with causes of infertility other than poor ovarian reserve&#xD;
&#xD;
          -  females suffering from congenital or acquired uterine anomalies &quot;will affect results&#xD;
             of implantation and pregnancy rates &quot;&#xD;
&#xD;
          -  females with focal uterine lesions anomalies &quot;will affect results of implantation and&#xD;
             pregnancy rates &quot;&#xD;
&#xD;
          -  BMI &gt;30 kg/m2 &quot;affecting quality of oocyte so affecting results&quot;.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moustafa Fouad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ainshams Maternity Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ebtihal ElTaieb, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ainshams Maternity Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed ElSaed, Master</last_name>
    <phone>01003704003</phone>
    <email>AhmedMohamedElSaed13@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AinShams University</name>
      <address>
        <city>Cairo</city>
        <zip>11856</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed ElSaed, Master</last_name>
      <phone>01003704003</phone>
      <email>AhmedMohamedElSaed13@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 9, 2021</study_first_submitted>
  <study_first_submitted_qc>October 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 9, 2021</last_update_submitted>
  <last_update_submitted_qc>October 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams Maternity Hospital</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed ElSaed Mostafa</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

